Compare Cenovus Energy Inc (CVE) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs DexCom, Inc. — how do they compare? Cenovus Energy Inc trades at $31.76 (market cap $57.90B), while DexCom, Inc. trades at $83.87 (market cap $31.86B). The key difference: Cenovus Energy Inc is the larger of the two by market cap, and Cenovus Energy Inc pays a 1.97% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and DexCom, Inc. for 62 Days on average.
| CVE | DXCM | |
|---|---|---|
Market Cap | $57.90B | $31.86B |
Volume | 7,863,588 | 3,607,070 |
Sector | Energy | Health |
52-Week High | $33.92 | $92.34 |
52-Week Low | $15.85 | $54.84 |
Typical Hold Time | 46 Days | 62 Days |
Enterprise Value | $63.84B | $31.32B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 20.96% ROE and 11.48% net margin, supported by recent earnings beats. Cash flow trends indicate operational strength, though net cash flow was negative $353 million in 2025. Analyst sentiment is mixed with 40.74% buy ratings, while recent news highlights growth potential and value attributes.
Outlook: CVE offers value with a low P/E of 12.43 and solid earnings growth projections, but faces headwinds from volatile oil prices and mixed technical indicators. Risks include energy market fluctuations and debt levels, though institutional interest remains steady. The stock presents a balanced opportunity for value investors seeking energy exposure.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
